AbVision

AbVision is a private U.S. biopharmaceutical company focused on immunology-based therapeutics for cancer and infectious diseases. The company develops therapeutic antibodies, vaccines, and cell therapy candidates and appears to concentrate its internal work at the preclinical and IND-enabling stages before seeking partners for downstream clinical development and commercialization. Its core technology platforms include SpeedyAb™ for antibody discovery, ImmunoBuster I+II™ for active-targeting and one-shot vaccine development, and TsKill™ for tumor-specific cell therapy. Publicly disclosed pipeline assets include checkpoint and innate immunity antibody programs such as AVI-102, AVI-103, and AVI-105, plus vaccine candidate AVI-205 for COVID-19. AbVision positions itself as an out-licensing and co-development partner for both preclinical drug candidates and platform technologies.